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Abstract
The increasing prevalence of N. gonorrhoeae strains exhibiting decreased susceptibility to third-generation cephalosporins
and the recent isolation of two distinct strains with high-level resistance to cefixime or ceftriaxone heralds the possible
demise of b-lactam antibiotics as effective treatments for gonorrhea. To identify new compounds that inhibit penicillin-
binding proteins (PBPs), which are proven targets for b-lactam antibiotics, we developed a high-throughput assay that uses
fluorescence polarization (FP) to distinguish the fluorescent penicillin, Bocillin-FL, in free or PBP-bound form. This assay was
used to screen a 50,000 compound library for potential inhibitors of N. gonorrhoeae PBP 2, and 32 compounds were
identified that exhibited .50% inhibition of Bocillin-FL binding to PBP 2. These included a cephalosporin that provided
validation of the assay. After elimination of compounds that failed to exhibit concentration-dependent inhibition, the
antimicrobial activity of the remaining 24 was tested. Of these, 7 showed antimicrobial activity against susceptible and
penicillin- or cephalosporin-resistant strains of N. gonorrhoeae. In molecular docking simulations using the crystal structure
of PBP 2, two of these inhibitors docked into the active site of the enzyme and each mediate interactions with the active site
serine nucleophile. This study demonstrates the validity of a FP-based assay to find novel inhibitors of PBPs and paves the
way for more comprehensive high-throughput screening against highly resistant strains of N. gonorrhoeae. It also provides
a set of lead compounds for optimization of anti-gonococcal agents.
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Introduction
Historically, b-lactams have been highly successful for the
treatment of bacterial infections, but the emergence of resistance
to these and other antibiotics has markedly limited the treatment
options in a number of pathogens. One notable example is Neisseria
gonorrhoeae, an obligate human pathogen and cause of the sexually
transmitted disease, gonorrhea. For over 40 years, gonorrhea was
treated with a single dose of penicillin, but the increasing
prevalence of strains exhibiting resistance to penicillin eventually
led to its withdrawal in 1986 by the Centers for Disease Control
and Prevention (CDC) as a recommended antibiotic for gonococ-
cal infections. With tetracycline and fluoroquinolones [1] being
withdrawn for similar reasons, only the extended-spectrum
cephalosporins, cefixime and ceftriaxone, remain as recommended
treatments in the U.S. However, during the last decade, strains
exhibiting decreased susceptibility to cefixime and ceftriaxone
have emerged in Japan and Europe [2,3,4,5,6,7], and the recent
isolation of two distinct strains in Japan and France with high-level
cefixime and ceftriaxone resistance (both with minimum inhibitory
concentrations (MICs) $2 mg/ml)) [8,9] signals the potential
demise of these antibiotics as effective treatments for gonorrhea
[10].
The lethal targets for b-lactams are penicillin-binding proteins
(PBPs) [11,12], which are transpeptidases that catalyze the
formation of peptide cross-links between adjacent glycan strands
during the final stages of peptidoglycan synthesis in bacteria.
Peptidoglycan envelops the bacterial cell and is essential for cell
growth, division and maintenance of cell shape [13]. PBPs share
a common penicillin-binding/transpeptidase domain with an
active site that contains three conserved motifs: SxxK, SxN and
KTG (where 6 is a variable residue) [14]. The SxxK motif
contains the serine nucleophile that attacks the carbonyl carbon of
the penultimate D-Ala of the peptide substrate or amide carbonyl
of the b-lactam ring. There are three classes of PBP: Class A PBPs
catalyze both glycosyl transferase and transpeptidase activities,
Class B catalyze only transpeptidase activity and Class C PBPs are
carboxypeptidases and/or endopeptidases. In most bacteria, Class
A and B PBPs are essential enzymes, whereas Class C PBPs can
often be deleted genetically without significant impact on cell
growth or morphology [15]. The genome of N. gonorrhoeae encodes
4 PBPs. PBPs 3 and 4 are Class C PBPs and are non-essential for
cell viability [16]. PBP 1 (Class A) and PBP 2 (Class B) are both
essential, but given that PBP 2 is inhibited at a 10-fold lower
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concentration of penicillin than PBP 1, it is the primary clinical
target in penicillin-susceptible strains [17,18].
N. gonorrhoeae develops chromosomally mediated resistance to b-
lactams through alteration of the PBP targets, increased expression
of the MtrC-MtrD-MtrE efflux pump and mutation of the porin
PorB1b that restricts entry into the periplasm [19,20]. The
primary step in this process is the acquisition of mutated forms of
PBP 2 that exhibit lowered reactivity with b-lactams and
compromise the effectiveness of these agents [21,22,23,24,25,26].
PBP 2 is essential for the growth of N. gonorrhoeae and is a validated
target for b-lactam antibiotics directed against this organism [18],
but its value as a clinical target has been diminished by mutations
associated with resistance. In order to develop new treatment
options for penicillin- and cephalosporin-resistant strains of N.
gonorrhoeae, new inhibitors of PBP 2 are needed. In this study, we
report the development of a high-throughput screening (HTS)
assay for PBPs that uses fluorescence polarization to detect binding
of the fluorescent b-lactam, Bocillin-FL [27]. We used this assay to
screen a 50,000 chemical library and identified a number of
compounds that inhibited PBP 2 activity in the micromolar range.
Of these, seven demonstrated antimicrobial activity against N.




A soluble construct of wild-type PBP 2 from the penicillin-
susceptible strain of N. gonorrhoeae FA19 was expressed and purified
as described previously [26]. Bocillin FLTM was obtained from
Invitrogen Inc. (Carlsbad, CA). Penicillin G and c-Globulins from
bovine blood (BGG) were purchased from Sigma (St. Louis, MO).
Prior to use, all reagents were diluted in an assay buffer comprising
50 mM potassium phosphate, pH 8, and 0.1 mg/ml BGG. The
DIVERSet library of 50,080 small lead compounds from Chem-
Bridge Corporation (San Diego, CA) was provided by the MUSC
Drug Discovery Core (DDC). Three laboratory strains of N.
gonorrhoeae–FA19 [28], penicillin-resistant FA6140 [29], and
cephalosporin-intermediate resistant CephI strain 35/02 [30]–
were from the laboratory collection of R. Nicholas (UNC-Chapel
Hill).
Fluorescence Polarization (FP) Measurements
Measurements of fluorescence and FP were performed on
a Spectramax M5 microplate reader (Molecular Devices, Sunny-
vale, CA) with excitation and emission wavelengths of 485 nm and
520 nm, respectively, using a 515 nm filter to block residual
excitation light and to minimize background interference. Black,
shallow 384-well micro plates (ProxiPlate TM –384 F Plus,
PerkinElmer) were used to record data. To minimize the
polarization effects from any fluorophore bound to the surface of
the well, both excitation and emission data were recorded from the
top of the well. Reading time was 100 ms per well. Fluorescence
polarization was quantified in millipolarization units (mP) accord-
ing to the equation, mP=10006[(Iv 2 G.Ih)/(Iv + G.Ih)], where Iv
and Ih are parallel and perpendicular emission intensity measure-
ments, respectively, corrected for background (buffer), and G is the
instrument-dependent correction coefficient, defined as a ratio of
sensitivities of the detection system for vertically and horizontally
polarized light. Using the equation G = Iv/Ih and SoftMaxH Pro
Data Acquisition & Analysis Software (Molecular Devices,
Sunnyvale, CA), the G-factor was determined with dilution series
of Bocillin-FL-only (free tracer). The assay window (DmP) was
defined as the difference between protein-tracer sample and free-
tracer, i.e. DmP = mPs – mPfree, and is a measure of the maximum
specific binding.
FP Assay Optimization
To calculate the G-factor, FP was measured in 10 ml reaction
volumes for free Bocillin-FL at concentrations of 0.2, 0.5, 1, 2, 3,
and 4 mM, where the FP signal of the fluorescent tracer was low
and stable. The optimal tracer-to-protein ratio was determined in
the binding experiments with increasing concentrations of PBP 2
(0.02–4 mM). FP was recorded after shaking the plate for 2 min
followed by 30 min incubation, at which point the reaction
reached its steady state (data not shown). Each experiment was
performed in quadruplicate at room temperature.
To evaluate the performance of the assay, steady-state
concentration-response experiments were carried out using
penicillin G in a competition assay with Bocillin-FL. Penicillin G
(0.05–1000 mM) was mixed with 1 mM PBP 2 and 1 mM Bocillin-
FL, followed by a 1 hr incubation. The positive (Pc) and negative
(Nc) controls were defined as the FP of the Bocillin-FL - protein
and of the free tracer, respectively, in the absence of penicillin G.
The FP of the Bocillin-FL - protein at 100 mM penicillin G was
defined as a displaced tracer control (Dc). Since DMSO was used
as a solvent in the compound library, the effect of 10% DMSO on
the FP-binding assay was also determined. Data points were
normalized to the maximum specific binding, which defines
complete saturation of PBP 2 by Bocillin-FL in the absence of
penicillin G, and IC50 values were determined using non-linear
regression analysis using GraphPad Prism version 4.00 for
Windows (GraphPad Software, Inc, San Diego, CA).
Assay performance was assessed using the following parameters:
the signal-to-noise ratio S/N = (mpc-mnc)/SDnc, Z9 and Z factors.
The latter were calculated as Z9=12 (3SDpc +3SDnc)/(mpc-mnc)
and Z= 12 (3SDpc +3SDdc)/(mpc-mc), where SDpc, SDnc, SDdc are
standard deviations and mpc, mnc, mdc are means of recorded
polarization values of Pc, Nc, and Dc, respectively [31].
High-throughput Assay and Screening for the Inhibitors
HTS screening against the ChemBridge DIVERSet library was
carried out under the following conditions: 1 ml of each compound
(10% DMSO final) in duplicate was pre-incubated with 9 ml of
PBP 2 for 1 h at room temperature, followed by additional 30 min
incubation with 2 ml Bocillin-FL (0.87 mM PBP2: 1 mM Bocillin-
FL final). In addition to samples with the compounds, each plate
also contained 2 background wells (12 ml buffer only), and at least
4 wells each for Pc, Nc, and Dc reactions. All samples used for
background measurements or controls included 10% DMSO.
Initial screening was carried out with 10 mM cocktails of 10
compounds (giving a final concentration of 100 mM for each
compound). Compounds from cocktails that showed 80% or more
reduction in DmP compared to maximum binding (DmPmax = Pc
– Nc) were then tested individually. The auto fluorescence of each
compound was also tested individually.
Concentration-response Experiments
Concentration-response experiments with the individual com-
pounds that demonstrated $50% DmP reduction compared to
maximum binding were conducted using FP-based and SDS-
PAGE-based steady-state binding assays. For the FP experiments,
0.01–200 mM of each potential hit was incubated with PBP 2
(1 mM) for 1 h, followed by an additional 30 min incubation with
1 mM Bocillin-FL to detect the residual activity of the labeled
penicillin binding. For the SDS-PAGE-based concentration-re-
sponse experiments, PBP 2 (1 mM) in 50 mM sodium phosphate,
0.01% Triton X-100, pH 8 was incubated with 0.05–1000 mM of
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a compound for 1 h, followed by additional 15 min incubation
with 10 mM Bocillin-FL. The reaction was stopped by mixing each
sample with 5 X SDS-loading buffer, followed by boiling for
2 min. The samples were submitted to electrophoresis on 10%
Mini-Protean TGXTM SDS-PAGE gels (Bio-Rad, Hercules, CA)
to separate bound PBP 2 from free ligand. At least two
independent reactions were performed in duplicate at each
concentration of an inhibitor. Gels were visualized by UV using
a Kodak EDAS 290 imaging system (Scientific Imaging Systems
Eastman Kodak, New Haven, CT, USA) and the protein bands
were stained with Coomassie to verify equal loading. Densitometry
was performed with ImageJ 1.37v program (National Institutes of
Health, USA, http://rsb.info.nih.gov/ij/). In both methods, data
points were normalized to the maximum value of the fluorescence
intensity, which defines complete saturation of PBP 2 by Bocillin-
FL in the absence of compound, and IC50 values of the inhibitors
were defined as the concentration of a compound at 50% of the
residual activity of Bocillin-FL and calculated using GraphPad
Prism (see above).
Antimicrobial Susceptibility Testing
Three strains of N. gonorrhoeae were used in susceptibility tests: 1)
FA19, a penicillin-and cephalosporin-susceptible strain; 2)
FA6140, a penicillin-resistant but cephalosporin-susceptible strain;
and 3) 35/02, a penicillin-resistant and cephalosporin intermedi-
ate-resistant strain. The disc diffusion zone method was applied for
preliminary testing of ‘‘hits’’ identified in the screening process
[32]. For this method, 100 ml of a cell suspension (,16107
bacteria) was added to 3 ml of GCB top agar (GC Broth
containing 0.75% agar) at 50oC, which was then added to GCB
plates and allowed to solidify. Five ml of each compound (5 mg) was
added separately to antibiotic susceptibility discs (BBLTM, BD,
Franklin Lakes, NJ), the discs were placed on top of plates, and the
plates were incubated overnight in a 4% CO2 incubator at 37
oC.
Those compounds that produced a visible zone of inhibition were
then tested for their MICs on agar plates as described [33]. Briefly,
GCB agar plates containing increasing amounts of the tested
compounds were spotted with 56104 cells. The lowest concentra-
tion of the test compound that prevented growth of ,5 colonies
was defined as the MIC. These experiments were repeated three
times, with each experiment producing similar results.
Molecular Modeling of PBP2 Inhibitors
Modeling, simulations and visualizations were performed using
Molecular Operating Environment (MOE) Version 2011.10
(Chemical Computing Group Inc., Montreal, Canada). The
crystal structure of wild-type N. gonorrhoeae PBP 2 was used as the
starting model for docking simulations (PDB:3EQU; [26]).
Following protonation of the main chain at pH 7.5 and addition
of salt at a concentration of 0.2 M, the structure was energy
minimized using the Amber99 forcefield and Born solvation
model. Ligands corresponding to the 7 compounds that displayed
antimicrobial activity against N. gonorrhoeae were prepared in
MOE, and also protonated at pH 7.5 with a salt concentration of
0.2 M. The entire protein surface was used for the simulations, in
which PBP 2 was held rigid and the ligand was flexed. Five
hundred poses per ligand were derived using triangle-matching
placement with London dG scoring. The top 250 poses were then
refined using forcefield placement and affinity dG scoring, leading
to a final database of 1750 poses for the seven compounds. All
poses within the active site were then energy minimized using the
Amber99 forcefield and Born solvation model, with both PBP 2
and the ligand allowed to flex.
Results
Development of the Fluorescence Polarization Assay
Initial experiments were performed to elucidate the minimal
amounts of Bocillin-FL and PBP 2 that give the largest range of
specific binding. The mP recorded for free Bocillin-FL in the
range of 0.2–4 mM was 40–65 mP (Fig. 1A). Based on the
results of steady-state binding experiments using variable
concentrations of PBP 2 and Bocillin-FL, the optimal assay
window (DmP) was 119 mP at a protein-Bocillin-FL ratio of
1:1 mM. At this ratio, the total fluorescence of Bocillin-FL was
not significantly affected by protein binding (Fig. 1B). The
average value of the G-factor coefficient used to correct mP
measurements for the instrument bias was 1.060.01. This was
determined within a 0.2–4 mM concentration range of free
Bocillin-FL and used in subsequent FP experiments, including
the HTS.
Penicillin G was used to evaluate and validate the assay for
HTS. The IC50 values of penicillin G for PBP 2 were determined
in a FP-based competition assay with and without 10% DMSO
(Fig. 2) and were 1.0 mM (95% confidence interval 0.9–1.2 mM,
R2= 0.99) and 1.4 mM (95% confidence interval 1.2–1.5 mM,
R2= 0.98), respectively. The statistical parameters, including
a signal-to-noise ratio .20, and Z9- and Z- factors $0.64,
indicated the sensitivity of the FP assay and demonstrated its
suitability for HTS (Table 1 and Fig. S1).
High-throughput Assay for Inhibitors of N. gonorrhoeae
PBP 2
The FP assay was then employed in HTS of the ChemBridge
DIVERset chemical library to find potential inhibitors of N.
gonorrhoeae PBP 2. This is a diversity library of small molecules
filtered for the inclusion of desirable drug-like features and
exclusion of non-selective toxic groups. In one published
example of HTS against zebra fish embryos using a subset of
this library, the toxicity rate was 2% [34] and for the full
library we have observed overall toxicity in the range of 3%,
even as pooled compounds (YKP, personal observation). In the
initial screening of 50,080 compounds (present as cocktails of 10
compounds), 58 cocktails exhibited $80% inhibition of Bocillin-
FL binding to PBP 2 (Fig. 3). Each of the 580 compounds was
then tested individually and 32 of these demonstrated more
than 50% inhibition (Tables S1, S2). None of the ‘‘hits’’ were
autofluorescent at the wavelengths used for the FP assay, thus
paving the way for further characterization.
Concentration-response Experiments
To characterize the inhibitory activity of each of the 32 hits,
concentration-response experiments were performed using the FP-
based binding assay in which 0.01–200 mM of each compound
was incubated with 1 mM of both PBP 2 and Bocillin-FL. Three
compounds failed to show a concentration-dependent response
and were excluded from further study. A cephalosporin, which
had an IC50 of 3 mM (the lowest of all the ‘‘hits’’), was also
excluded since the goal was to identify non-b-lactam inhibitors;
however, the successful identification of a b-lactam was validation
of the effectiveness of the assay (Fig. S2 and Table S3). IC50 values
for 24 of the remaining 28 compounds (four compounds were not
available from ChemBridge) were also measured in an SDS-PAGE
concentration-response assay using a 0.05–1000 mM concentra-
tion range for the inhibitor with 1 mM PBP 2 and 10 mM of
Bocillin-FL to confirm their binding activities. Triton X-100
(0.01%) was included in this assay to eliminate ‘‘promiscuous’’
inhibitors (e.g. those that inhibit by non-specific aggregation
High-Throughput Screening against PBP 2
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[35,36]). Six compounds failed to show concentration-dependent
inhibition in the presence of Triton X-100 and were therefore
excluded. The remaining 18 compounds had IC50 values in the
range of 50–900 mM (Table 2 and Table S3). Representative
examples are shown in Fig. 4 and an example of an SDS-PAGE
gel used to determine the IC50 for compound 7 is shown in Fig.
S3.
Antimicrobial Susceptibility Testing
The 18 compounds were then tested for their ability to suppress
the growth of N. gonorrhoeae FA19 using the disc diffusion zone
method. Eleven compounds did not suppress growth and were
excluded (data not shown). For the remaining 7 compounds, the
minimal inhibitory concentrations (MICs) were determined
against three N. gonorrhoeae strains: FA19, a penicillin-susceptible
strain [28]; FA6140, a penicillin-resistant but cephalosporin-
susceptible strain [29]; and 35/02, a strain that exhibits in-
termediate resistance to cephalosporin (CephI)[30]. The IC50
values and MICs of the seven compounds are shown in Table 2
and their respective structures are shown in Fig. 5. The MIC
values ranged from 2–32 mg/ml and all except for compound 4
were higher in resistant strains compared to FA19. The best
compound overall (7) exhibited an MIC of 2 mg/ml (5.6 mM)
against FA19 and 8 mg/ml (23.4 mM) against both FA6140 and
35/02.
Docking Simulations
In order to identify potential binding sites and evaluate the
mode of interaction between the experimental compounds and
PBP 2, we probed the entire surface of the protein with the
inhibitors using molecular docking simulations. Five hundred
random starting positions for each compound were generated and
the best 250 scoring poses were refined and ranked. Top poses
within the active site were energy minimized, with both protein
and inhibitor bonds allowed to rotate. The presence of a refined
pose within the active site of PBP 2 in the top ten poses was taken
as a high probability of selective interaction (Fig. S4). Hit rates to
the active site varied for each compound as follows: Compound 1 -
5/10, Compound 2 - 1/10, Compound 3 - 1/10, Compound 4 -
7/10, Compound 5 - 6/10, Compound 6 - 4/10, and Compound
7 - 3/10. These data indicate a high propensity for all the active
compounds to bind to the active site. For compound 2, the
number one pose out of 250 refined poses docked within the active
site (Fig. 6A). There are three predicted contacts between this
compound and PBP 2: a hydrogen bond between the ligand
carbonyl and the hydroxyl of Ser310 (the active site nucleophile),
an interaction between the amide nitrogen of Thr347 and the
nitrous acid of compound 2, and an arene-hydrogen interaction
between the conjugated phenyl ring of compound 2 and Asn364.
The phenyl ring interacts with a shallow hydrophobic pocket
formed by Phe420 and Tyr422 on one side, but is solvent exposed
on the other. Compound 7 was found in the active site in the fifth
pose out of 250 refined poses (Fig. 6B). In this model, hydrogen
Figure 1. Optimization of the fluorescence polarization (FP) assay. A. Fluorescence polarization (mP) of free Bocillin-FL at various
concentrations from 0.002 to 4 mM. B. Binding experiments with Bocillin-FL (1 mM) and PBP 2 at various protein concentrations from 0.2 to 4 mM.
Fluorescence of Bocillin-FL – PBP2 was measured in relative fluorescence units (RFU) (open circles). Maximum specific binding (triangles), i.e. assay
window (DmP), was determined by FP. Assay window is defined as the difference between FP of protein-tracer sample and free-tracer, i.e. DmP =
mPs – mPfree. In all experiments, the data points represent the mean 6 standard deviation of four replicate experiments at each concentration of
Bocillin-FL or PBP 2.
doi:10.1371/journal.pone.0044918.g001
Table 1. Statistical parameters of the FP assay.
Pc 6 SD (mP) Nc 6 SD (mP) S/N Z9-factor Dc 6 SD (mP) Z-factor
Optimization 17269 (n = 8) 5365 (n = 8) 23.8 0.65 5565 (n = 8) 0.64
HTS assay 171611 (n = 379) 4668 (n = 368) 15.4 0.55 46.569.7 (n = 246) 0.51
The performance of the assay was determined during initial optimization and after the HTS assay. Pc is the mean FP signal of PBP 2-bound tracer control, Nc is the mean
FP signal of free Bocillin-FL, and Dc is the FP signal in the presence of 100 mm penicillin G. S/N (signal-to-noise) and the Z factors are as defined in Material and Methods.
(n = number of measurements). See also Fig. S1).
doi:10.1371/journal.pone.0044918.t001
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bonds are observed between Asp346 and the secondary amine of
the thiazolidine ring, and between the hydroxyl of Tyr544 and the
carbonyl of compound 7. Additionally, there are arene-hydrogen
interactions from the thiazolidine ring to both Thr347 and Ser362.
The bromine atom appears to be totally solvated and does not
interact with the protein directly. Overall, the docking results
suggest that all of the seven compounds can bind within the active
site of PBP 2, although precise details of binding can only be
revealed by experimental structural studies.
Discussion
As important targets for b-lactams and against the background
of increasing clinical resistance to existing antibiotics, much effort
has been directed toward developing new inhibitors of PBPs. Some
approaches have sought to adapt the b-lactam moiety by, for
instance, incorporating elements of the peptide substrates onto one
of the R1 or R2 side chains [37,38,39], while others have
synthesized compounds that mimic the tetrahedral intermediates
of the reaction, including phosphonates and boronates
[40,41,42,43]. Given the wealth of structural information for
several clinically important PBPs, in silico docking has also been
employed in some systems [44]. To contribute to this effort, we
have developed a high-throughput assay for PBPs that measures
the fluorescence polarization (FP) of Bocillin-FL [27] and used it to
screen for potential inhibitors of N. gonorrhoeae PBP 2 from a library
of 50,080 compounds. After eliminating those that acted pro-
miscuously, did not demonstrate a concentration-dependent
inhibition, or were b-lactams, 18 compounds were examined in
more detail, and 7 of these exhibited antimicrobial activity against
N. gonorrhoeae, including PenR and CephI strains. To the best of our
knowledge, this is the first report of high-throughput screening
(HTS) against a PBP.
Development of the assay was made possible by using
fluorescence polarization to distinguish between the fluorescent
penicillin (Bocillin-FL) remaining in solution from that bound to
the PBP target, an approach first suggested by Zhao et al. [27]. The
robustness and sensitivity of the assay is supported by the large
assay window and Z factor. As a safeguard against any false
positives arising from the FP-based assay, an SDS-PAGE
competition assay was used to confirm inhibition of PBP 2. The
identification of a cephalosporin with an IC50 of 3 mM against
PBP2 was demonstration of the validity of the assay.
Out of the seven compounds that exhibited the lowest IC50
values for PBP 2 (, 50 mM) and good anti-gonococcal activity,
two of these (compounds 4 and 5) contain a sulfonamide group
between two aromatic rings. Interestingly, a sulfonamide of similar
structure was identified recently as an inhibitor of PBP2a from
methicillin-resistant Staphylococcus aureus (MRSA) [45]. Similar to
compounds 4 and 5, compound 1 has two aromatic rings joined
by a bridging group reminiscent of the sulfonamide inhibitors and
showed reasonable antimicrobial activity against FA19, but less so
against 6140 and 35/02. Compound 2 also possesses two aromatic
rings, one of which contains a potentially reactive hydroxyl
Figure 2. Inhibition of FP of Bocillin-FL and PBP 2 by increasing amounts of penicillin G. Assays contained variable concentrations of
penicillin G (0.05–1000 mM) with fixed concentrations of PBP 2 (1 mM) and Bocillin-FL (1 mM) with or without 10% DMSO. The solid line represents
data for PBP 2 without DMSO and the dashed line is PBP 2 with DMSO. In all experiments, the data points represent the mean 6 standard deviation
of four replicate experiments at each concentration of penicillin G.
doi:10.1371/journal.pone.0044918.g002
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nitrobenzaldehyde group. This compound demonstrated moder-
ate antibacterial activity against FA19, with higher MIC values
against FA610 and 35/02. It was the most successful compound
during the docking simulations and in this model there is an
interaction with the serine nucleophile of PBP 2 (Ser310).
Compound 6 exhibited the lowest IC50 value (49 mM) with good
MICs against FA19 (4 mg/ml) and the two antibiotic-resistant
strains (both were 8 mg/ml). Compound 7 showed rather
moderate enzyme inhibition (IC50 = 153 mM) but exhibited the
highest antimicrobial activity in all N. gonorrhoeae strains. In-
terestingly, this compound contains a thiazolidine ring, a feature of
penicillin antibiotics and arylalkylidene iminothiazolidin-4-ones,
which inhibit some PBPs in vitro and shows antimicrobial activity
[46]. Compound 7 was also successful in the docking simulations
and there are predicted interactions with Ser310. The resem-
blance of compound 7 to a b-lactam-like compound led us to
determine whether there is a covalent interaction with PBP 2, but
no increase in mass of the protein was observed by mass
spectrometry (data not shown). Finally, compound 3 is probably
the least promising candidate at this stage since it has a relatively
high IC50 against PBP 2 and its MIC values against the N.
gonorrhoeae strains are correspondingly weak.
Overall, there was relatively weak correlation between IC50 and
MIC values for the seven compounds, but this is expected for initial
hits from HTS because there are a variety of factors that determine
the MIC. Since N. gonorrhoeae expresses two essential PBPs, PBP 1
could be the lethal target for a given compound in addition to, or
independent of, PBP 2. The outer membrane of Gram-negative
bacteria is a barrier to hydrophobic compounds [47] and the
lipooligosaccharide structure of N. gonorrhoeae also impacts perme-
ability. In addition, entry of hydrophilic compounds into the
periplasm is influenced by porins and the action of efflux systems can
remove compounds from the periplasm. Both of the antibiotic
resistant strains (FA6140 and 35/02) contain a mutation in the
promoter of mtrCDE that increases expression of the MtrC-MtrD-
Figure 3. Initial HTS of 50,080 small lead compounds from DIVERSet ChemBridge Library was performed using cocktails of 10
different compounds (10X cocktails). Each plate contained duplicate samples of 10X cocktails with PBP 2 and Bocillin-FL. Data points denoted by
the black dots represent the percent of inhibition for each 10X cocktail determined using the average of two sample FP measurements, and the
means of free Bocillin-FL (Nc) and bound Bocillin–FL (Pc) controls recorded in quadruplicate for each corresponding plate. Data points of the
displaced tracer controls (Dc - the FP of the Bocillin-FL - protein at 100 mM penicillin G), denoted by open circles, represent the percent of inhibition
based on the average of four FP measurements. Fifty-two plates with 96610X cocktails each and one plate with eight610 X cocktails were screened.
The box indicates the 58 cocktails that exhibited $80% inhibition of Bocillin-FL binding to PBP 2.
doi:10.1371/journal.pone.0044918.g003
Table 2. IC50 values and antimicrobial activities of seven
compounds identified by high-throughput screening against
PBP 2 from N. gonorrhoeae strain FA19.
Compound #
IC50
(mM; mg/ml) MIC (mg/ml)
FA19 35/02 FA6140
1 221/135 4 16 16
2 128/38 4 8 16
3 898/208 16 32 32
4 50/20 16 16 16
5 56/20 8 16 16
6 49/38 4 8 8
7 153/54 2 8 8
doi:10.1371/journal.pone.0044918.t002
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MtrE efflux pump. In addition, both strains harbor an altered porB1B
allele encoding the major outer membrane porin, which decreases
influx of antibiotics into the periplasmic space [17,30,48]. Hence,
the ability of the different compounds to permeate porins or to be
substrates of the efflux pump can have a profound impact on
antibiotic efficacy [19]. It is also possible that someof the compounds
with lowMICs are cytotoxic toN. gonorrhoeae. Further investigation of
the compounds is therefore necessary to establish their in vivo
mechanism of antimicrobial activity.
In conclusion, an FP-based HTS has generated several
inhibitors of PBP 2 and several show promising antimicrobial
activity against PenR and CephI strains of N. gonorrhoeae. Such
compounds require further study to confirm their mechanism of
action, followed by chemical optimization to improve their
efficacy. The development of this assay paves the way to screen
using larger compound libraries and against variants of PBP 2 that
contribute to third-generation cephalosporin resistance.
Figure 4. IC50 values of three representative hits from HTS for inhibition of acylation of PBP 2 by Bocillin-FL. IC50s of the inhibitors
were determined by SDS-PAGE-based concentration-response assays using a 0.05–1000 mM concentration range for the inhibitors with 1 mM PBP 2
and 10 mM of Bocillin-FL. Triton X-100 (0.01%) was included to eliminate promiscuous inhibitors. A. Compound 2 (in Table 2). B. Compound 4. C.
Compound 7. In all experiments, the data points represent the mean6 standard deviation for two replicate (compounds 4 and two) or four replicate
(compound 7) experiments at each concentration of inhibitor.
doi:10.1371/journal.pone.0044918.g004
Figure 5. Structures of seven compounds that exhibited antimicrobial activity against N. gonorrhoeae. Compound numbers correspond
with those in Table 2.
doi:10.1371/journal.pone.0044918.g005
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Supporting Information
Figure S1 Millipolarization values (mP) of positive control (Pc),
negative control (Nc) and displaced tracer control (Dc) for all
measurements recorded during the HTS, including the initial
optimization. The data points represent mP measurements
(n = sample number).
(TIF)
Figure S2 Four of the 32 compounds that were excluded from
further study. A. Compounds 30, 31, 32 failed to show
a concentration-dependent response in FP-based experiments.
IC50s of the compounds were determined by FP-based concen-
tration-response assays using a 0.01–200 mM concentration range
for the compounds with 1 mM PBP 2 and 1 mM of Bocillin-FL. In
all experiments, the data points represent the mean 6 standard
deviation over four replicate experiments. B. Compound 29 had
an IC50 of 3 mM (the lowest of all the ‘‘hits’’), but is
a cephalosporin.
(TIF)
Figure S3 SDS-PAGE-based analysis of the inhibitory activity of
compound 7 against PBP 2 (IC50 = 153 mM). PBP 2 (1 mM) in
50 mM sodium phosphate, 0.01% Triton X-100, pH 8 was
incubated with 0.05–1000 mM of compound 7 for 1 h, followed by
15 min incubation with 10 mM Bocillin-FL. The reaction was
stopped by mixing with 5 X SDS-loading buffer, followed by
boiling for 2 min. 10% SDS-PAGE gels was then used to separate
bound PBP 2 from free ligand. At least two independent reactions
were performed in duplicate at each concentration of the inhibitor.
Gels were visualized by UV (top panel) to measure IC50 and the
same gels were stained with Coomassie Brilliant Blue R-250 to
verify equal loading of protein (lower panel).
(TIF)
Figure S4 Docking of compounds as surface probes with PBP 2.
Depicted are the top 10 poses for each compound (numbered 1–7)
from 250 refined poses, as described in the Material & Methods.
PBP 2 is displayed as a grey surface and is in the same orientation
as Fig. 6. The active site region is colored green and the
compounds are displayed in bond format and colored orange.
(TIF)
Table S1 The layout of the 384-well plates used for the high-
throughput screening of the 50,080 compound Chembridge
DIVERSet library. Compounds were present as cocktails of 10
compounds each (10X cocktails). In total, fifty-two plates with 96
cocktails and one plate with 8 cocktails were screened. The wells
are numbered according to the scheme below, where each well
contains one cocktail and each cocktail is present twice for two
independent measurements. Rows J-P in each plate were not used.
Dc= displaced tracer control, Bk= blank, Nc= negative control
and Pc= positive control.
(DOCX)
Table S2 Analysis of the 58 cocktails showing $80% inhibition
of Bocillin-FL binding to PBP 2.
(DOCX)
Table S3 Analysis of 32 individual compounds that exhibited
$50% inhibition of Bocillin-FL binding to PBP 2.
(DOCX)
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Figure 6. Docking of two compounds into the structure of N. gonorrhoeae penicillin-binding protein 2. The main chain of PBP 2 is shown
as a grey ribbon, residues of the active site motifs of PBPs are shown with green bonds and additional amino acids that are predicted to form
interactions with the ligand are shown in blue. A. compound 2. B. compound 7. Figure prepared with MOE 2011.10 (Chemical Computing Group
Inc.).
doi:10.1371/journal.pone.0044918.g006
High-Throughput Screening against PBP 2
PLOS ONE | www.plosone.org 8 September 2012 | Volume 7 | Issue 9 | e44918
References
1. Centers for Disease Control (CDC) (2007) Update to CDC’s sexually transmitted
diseases treatment guidelines, 2006: fluoroquinolones no longer recommended
for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 56:
332–336.
2. Akasaka S, Muratani T, Yamada Y, Inatomi H, Takahashi K, et al. (2001)
Emergence of cephem- and aztreonam-high-resistant Neisseria gonorrhoeae that
does not produce beta-lactamase. J Infect Chemother 7: 49–50.
3. Muratani T, Akasaka S, Kobayashi T, Yamada Y, Inatomi H, et al. (2001)
Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant
Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 45: 3603–3606.
4. Tapsall J, Read P, Carmody C, Bourne C, Ray S, et al. (2009) Two cases of
failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular
microbiological methods. J Med Microbiol 58: 683–687.
5. Golparian D, Hellmark B, Fredlund H, Unemo M (2010) Emergence, spread
and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased
susceptibility and resistance to extended-spectrum cephalosporins in Sweden.
Sex Transm Infect 86: 454–460.
6. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H (2010) Two cases
of verified clinical failures using internationally recommended first-line cefixime
for gonorrhoea treatment, Norway, 2010. Euro Surveill 15: pii: 19721.
7. Unemo M, Golparian D, Hestner A (2011) Ceftriaxone treatment failure of
pharyngeal gonorrhoeae verified by international recommendations, Sweden,
July 2010. Euro Surveill 16: 1–3.
8. Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, et al. (2011)
Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 17: 148–149.
9. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, et al. (2012) High-
level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel
penA mosaic allele in a successful international clone causes treatment failure.
Antimicrob Agents Chemother 56: 1273–1280.
10. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, et al. (2011) Is
Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed
characterization of the first strain with high-level resistance to ceftriaxone.
Antimicrob Agents Chemother 55: 3538–3545.
11. Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A (2006)
Penicillin binding proteins: key players in bacterial cell cycle and drug resistance
processes. FEMS Microbiol Rev 30: 673–691.
12. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P (2008) The penicillin-
binding proteins: structure and role in peptidoglycan biosynthesis. FEMS
Microbiol Rev 32: 234–258.
13. Vollmer W, Blanot D, de Pedro MA (2008) Peptidoglycan structure and
architecture. FEMS Microbiol Rev 32: 149–167.
14. Goffin C, Ghuysen JM (1998) Multimodular penicillin-binding proteins: an
enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev 62: 1079–
1093.
15. Ghosh AS, Chowdhury C, Nelson DE (2008) Physiological functions of D-
alanine carboxypeptidases in Escherichia coli. Trends Microbiol 16: 309–317.
16. Stefanova ME, Tomberg J, Olesky M, Holtje JV, Gutheil WG, et al. (2003)
Neisseria gonorrhoeae penicillin-binding protein 3 exhibits exceptionally high
carboxypeptidase and beta-lactam binding activities. Biochemistry 42: 14614–
14625.
17. Ropp PA, Hu M, Olesky M, Nicholas RA (2002) Mutations in ponA, the gene
encoding penicillin-binding protein 1, and a novel locus, penC, are required for
high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae.
Antimicrob Agents Chemother 46: 769–777.
18. Barbour AG (1981) Properties of penicillin-binding proteins in Neisseria
gonorrhoeae. Antimicrob Agents Chemother 19: 316–322.
19. Shafer WM, Folster JP, Nicholas RA (2010) Molecular mechanisms of antibiotic
resistance expressed by the pathogenic Neisseriae. In: Genco CA, L W, editors.
Neisseria: Molecular Mechanisms of Pathogenesis: Horizon Scientific Press. 245.
20. Nicholas RA, Davies C (2012) Structural Mechanisms of b-Lactam Antibiotic
Resistance in Penicillin-Binding Proteins.. In: Dougherty TJ, Pucci MJ, editors.
Antibiotic Discovery & Development: Springer-Verlag 397–425.
21. Brannigan JA, Tirodimos IA, Zhang QY, Dowson CG, Spratt BG (1990)
Insertion of an extra amino acid is the main cause of the low affinity of penicillin-
binding protein 2 in penicillin-resistant strains of Neisseria gonorrhoeae. Mol
Microbiol 4: 913–919.
22. Dowson CG, Jephcott AE, Gough KR, Spratt BG (1989) Penicillin-binding
protein 2 genes of non-beta-lactamase-producing, penicillin-resistant strains of
Neisseria gonorrhoeae. Mol Microbiol 3: 35–41.
23. Ameyama S, Onodera S, Takahata M, Minami S, Maki N, et al. (2002) Mosaic-
like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of
Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents
Chemother 46: 3744–3749.
24. Ito M, Deguchi T, Mizutani KS, Yasuda M, Yokoi S, et al. (2005) Emergence
and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure
of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother
49: 137–143.
25. Ochiai S, Sekiguchi S, Hayashi A, Shimadzu M, Ishiko H, et al. (2007)
Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2
for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother 60: 54–
60.
26. Powell AJ, Tomberg J, Deacon AM, Nicholas RA, Davies C (2009) Crystal
structures of penicillin-binding protein 2 from penicillin-susceptible and -
resistant strains of Neisseria gonorrhoeae reveal an unexpectedly subtle mechanism
for antibiotic resistance. J Biol Chem 284: 1202–1212.
27. Zhao G, Meier TI, Kahl SD, Gee KR, Blaszczak LC (1999) BOCILLIN FL,
a sensitive and commercially available reagent for detection of penicillin-binding
proteins. Antimicrob Agents Chemother 43: 1124–1128.
28. Maness MJ, Sparling PF (1973) Multiple antibiotic resistance due to a single
mutation in Neisseria gonorrhoeae. J Infect Dis 128: 321–330.
29. Danielsson D, Faruki H, Dyer D, Sparling PF (1986) Recombination near the
antibiotic resistance locus penB results in antigenic variation of gonococcal outer
membrane protein. Infect Immun 52: 529–533.
30. Lindberg R, Fredlund H, Nicholas R, Unemo M (2007) Neisseria gonorrhoeae
isolates with reduced susceptibility to cefixime and ceftriaxone: association with
genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents
Chemother 51: 2117–2122.
31. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for
Use in Evaluation and Validation of High Throughput Screening Assays.
J Biomol Screen 4: 67–73.
32. Bauer AW, Perry DM, Kirby WM (1959) Single-disk antibiotic-sensitivity testing
of staphylococci; an analysis of technique and results. AMA Arch Intern Med
104: 208–216.
33. Tomberg J, Unemo M, Davies C, Nicholas RA (2010) Molecular and Structural
Analysis of Mosaic Variants of Penicillin-Binding Protein 2 Conferring
Decreased Susceptibility to Expanded-Spectrum Cephalosporins in Neisseria
gonorrhoeae: Role of Epistatic Mutations. Biochemistry 49: 8062–8070.
34. Peterson RT, Link BA, Dowling JE, Schreiber SL (2000) Small molecule
developmental screens reveal the logic and timing of vertebrate development.
Proc Natl Acad Sci U S A 97: 12965–12969.
35. Feng BY, Shoichet BK (2006) A detergent-based assay for the detection of
promiscuous inhibitors. Nat Protoc 1: 550–553.
36. Shoichet BK (2006) Screening in a spirit haunted world. Drug Discov Today 11:
607–615.
37. Josephine HR, Kumar I, Pratt RF (2004) The perfect penicillin? Inhibition of
a bacterial DD-peptidase by peptidoglycan-mimetic beta-lactams. J Am Chem
Soc 126: 8122–8123.
38. Josephine HR, Charlier P, Davies C, Nicholas RA, Pratt RF (2006) Reactivity of
penicillin-binding proteins with peptidoglycan-mimetic beta-lactams: what’s
wrong with these enzymes? Biochemistry 45: 15873–15883.
39. Kumar I, Josephine HR, Pratt RF (2007) Reactions of peptidoglycan-mimetic
beta-lactams with penicillin-binding proteins in vivo and in membranes. ACS
Chem Biol 2: 620–624.
40. Silvaggi NR, Anderson JW, Brinsmade SR, Pratt RF, Kelly JA (2003) The
crystal structure of phosphonate-inhibited D-Ala-D-Ala peptidase reveals an
analogue of a tetrahedral transition state. Biochemistry 42: 1199–1208.
41. Pechenov A, Stefanova ME, Nicholas RA, Peddi S, Gutheil WG (2003) Potential
transition state analogue inhibitors for the penicillin-binding proteins. Bio-
chemistry 42: 579–588.
42. Nicola G, Peddi S, Stefanova ME, Nicholas RA, Gutheil WG, et al. (2005)
Crystal structure of Escherichia coli penicillin-binding protein 5 bound to
a tripeptide boronic acid inhibitor: a role for Ser-110 in deacylation
Biochemistry 44: 8207–8217.
43. Inglis SR, Zervosen A, Woon EC, Gerards T, Teller N, et al. (2009) Synthesis
and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39
inhibitors. J Med Chem 52: 6097–6106.
44. Miguet L, Zervosen A, Gerards T, Pasha FA, Luxen A, et al. (2009) Discovery of
new inhibitors of resistant Streptococcus pneumoniae penicillin binding protein (PBP)
2x by structure-based virtual screening. J Med Chem 52: 5926–5936.
45. Turk S, Verlaine O, Gerards T, Zivec M, Humljan J, et al. (2011) New
noncovalent inhibitors of penicillin-binding proteins from penicillin-resistant
bacteria. PLoS One 6: e19418.
46. Zervosen A, Lu WP, Chen Z, White RE, Demuth TP, et al. (2004) Interactions
between penicillin-binding proteins (PBPs) and two novel classes of PBP
inhibitors, arylalkylidene rhodanines and arylalkylidene iminothiazolidin-4-ones.
Antimicrob Agents Chemother 48: 961–969.
47. Nikaido H (1994) Prevention of drug access to bacterial targets: permeability
barriers and active efflux. Science 264: 382–388.
48. Olesky M, Hobbs M, Nicholas RA (2002) Identification and analysis of amino
acid mutations in porin IB that mediate intermediate-level resistance to penicillin
and tetracycline in Neisseria gonorrhoeae. Antimicrob Agents Chemother 46: 2811–
2820.
High-Throughput Screening against PBP 2
PLOS ONE | www.plosone.org 9 September 2012 | Volume 7 | Issue 9 | e44918
